News

Attentive Science Q&A with Kyle Kappeler 18th Nov 2020 

Kyle Kappeler recently joined Attentive Science as the Director of Toxicology.  He is responsible for the scientific oversight of the technical conduct, interpretation, analysis, documentation and reporting of Toxicology study results.  In addition, he will be providing study design consultation for clients as they work towards getting their product to the market. 

In this newsletter, we take a minute to interview Kyle to give all you the opportunity to get to know him a tad better…

Tell us a bit about your background?

I have over 10 years of toxicology experience with 8+ years of direct experience in the contract research environment with a primary focus in general toxicology.  I spent 2 years as a NIEHS post-doctoral fellow at The University of Arizona in the Department of Pharmacology and Toxicology researching the molecular response of arsenic exposure in skin cells.  After my fellowship ended, I gained most of my experience and knowledge in general toxicology having served as a Senior Toxicologist/Study Director at WIL Research and MRIGlobal in support of IND, Global Registration, and Food Safety Assessment submissions in accordance with FDA, OECD, US.E.P.A, ICH and/or EFSA guidelines for 6 years.  For the past 2 ½ years, I was the Director of Toxicology for CRL-Stilwell (formally Xenometrics and Citoxlab USA).  

You have worked at several companies over the last 8 years, what have you learned from the various companies and how will it influence your approach at Attentive Science?

The most important lessons I learned throughout my past experiences was being approachable and being hands on with everything you do.  Adopting these philosophies have served me well both as a Study Director and Director.  As a Study Director, I would make it a point to be directly involved with the conduct of the study and not be a “remote” monitoring Study Director.  That direct involvement allowed me to learn the details that don’t show up in the data files that can help troubleshoot any study issues or provide more context to the data.  Also, being involved in the laboratory helps to build the trust of the study team (technical staff and client).  Having trust between myself and the study team resulted in direct communication about the study and produces an overall better experience for the client.  Furthermore, building trust between myself and the technical team also served to break-down the stigma that study directors are “unapproachable”.  I valued the input I received from the technicians and in several circumstances, they felt empowered to bring protocol/study issues to my attention, which prevented potential problems from escalating.  Taking the lessons I learned as a Study Director and the best approaches from people I deemed as mentors, I was able to mold a managerial style that fits my personality and is authentic to me.  I try to hold myself accountable to the group and lead by example, which I hope raises the expectation bar for everyone else to follow.  

What should clients expect of you as the Director of Toxicology?

I plan to be involved with each and every study that is conducted at Attentive Science.  Some of the times, I may be providing scientific feedback for a study related activity, report reviews, study design consultations or at times, I might be your Study Director.  As a client, you will no-longer have to guess “who” you need to contact to get your study specific requests addressed.  If you don’t have an already established relationship with an Attentive Science member, I will serve as a direct contact to you and can be reached anytime by email or by cellphone.  In addition, I will be promoting the “study team” mentality, which includes not only members of Attentive Science, but the client as well.  Keeping you the client informed/involved in the conduct of the study, is in my opinion, a critical piece of the puzzle to help generate a high-quality study.  Having a fully engaged study team allows for direct communication and, as a client, you will never have to wonder how your study is going.   

What excites you most about joining Attentive Science?  

I’m most excited to be working with a boutique, flexible, experienced and team-oriented company.  I think being small is an advantage in the current environment because we will constantly re-evaluate our processes, receive constructive/meaningful input from our clients, which will be used to make any appropriate changes in a timely manner to avoid inefficiency and becoming ineffective.  Lastly, I’m very grateful to have the opportunity to work along-side Dr. Botchway (CEO), Phil Atterson (COO), and the rest of the Attentive Science team as we grow this company to meet the ever growing needs of the non-clinical research industry.

If you have any questions or comments, please use the contact link within the Attentive Science website. The Attentive Science team is looking forward to working with you. 

Attentive Science Announces Hire of Chief Operating Officer 10th Nov 2020

STILWELL, KS, November 10, 2020 – Attentive Science, a leading provider of drug discovery and development services, announced today that Phil Atterson, BSc, MSc, has joined the Company as Chief Operating Officer effective 10th November, 2020.


"Phil’s extensive experience in the CRO industry will help us grow Attentive Science by providing broader expertise to our clients and staff," said Dr. Alfred Botchway, the Company’s Chief Executive Officer. "In this industry it is important to have an understanding of the client experience and expectations and this is something that Phil excels in. I am excited to work once again with Phil here at Attentive Science."

Prior to joining Attentive Science, Mr. Atterson established a reputation as a leader in contract research organizations where he worked in roles of increasing responsibility for more than four decades, working through technical positions, as a study director into management. He started his career in the Pharmacology Department at Huntingdon Research Centre in the UK before moving to Quintiles preclinical. After moving to the US to establish a Safety Pharmacology group at Quintiles in Kansas City he transferred to WIL Research to head up their Pharmacology team. He returned to Kansas City, rejoining colleagues at Xenometrics. Prior to joining Attentive Science, Phil was site director for Citoxlab USA in Kansas.

“I am delighted to join Attentive Science,” said Mr. Atterson. "The team that Alfred has already on boarded are people I have worked with previously who I know and respect. This group has demonstrated success in the past and I know that, we will continue to provide our clients with the high quality and personal experience that they expect from us."